Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Grafts Derived from an α-Synuclein Triplication Patient Mediate Functional Recovery but Develop Disease-Associated Pathology in the 6-OHDA Model of Parkinson's Disease

Shrigley, Shelby LU orcid ; Nilsson, Fredrik LU orcid ; Mattsson, Bengt LU ; Fiorenzano, Alessandro LU ; Mudannayake, Janitha LU orcid ; Bruzelius, Andreas LU ; Ottosson, Daniella Rylander LU orcid ; Björklund, Anders LU orcid ; Hoban, Deirdre B LU and Parmar, Malin LU orcid (2021) In Journal of Parkinson's Disease 11(2). p.515-528
Abstract

BACKGROUND: Human induced pluripotent stem cells (hiPSCs) have been proposed as an alternative source for cell replacement therapy for Parkinson's disease (PD) and they provide the option of using the patient's own cells. A few studies have investigated transplantation of patient-derived dopaminergic (DA) neurons in preclinical models; however, little is known about the long-term integrity and function of grafts derived from patients with PD.

OBJECTIVE: To assess the viability and function of DA neuron grafts derived from a patient hiPSC line with an α-synuclein gene triplication (AST18), using a clinical grade human embryonic stem cell (hESC) line (RC17) as a reference control.

METHODS: Cells were differentiated into... (More)

BACKGROUND: Human induced pluripotent stem cells (hiPSCs) have been proposed as an alternative source for cell replacement therapy for Parkinson's disease (PD) and they provide the option of using the patient's own cells. A few studies have investigated transplantation of patient-derived dopaminergic (DA) neurons in preclinical models; however, little is known about the long-term integrity and function of grafts derived from patients with PD.

OBJECTIVE: To assess the viability and function of DA neuron grafts derived from a patient hiPSC line with an α-synuclein gene triplication (AST18), using a clinical grade human embryonic stem cell (hESC) line (RC17) as a reference control.

METHODS: Cells were differentiated into ventral mesencephalic (VM)-patterned DA progenitors using an established GMP protocol. The progenitors were then either terminally differentiated to mature DA neurons in vitro or transplanted into 6-hydroxydopamine (6-OHDA) lesioned rats and their survival, maturation, function, and propensity to develop α-synuclein related pathology, were assessed in vivo.

RESULTS: Both cell lines generated functional neurons with DA properties in vitro. AST18-derived VM progenitor cells survived transplantation and matured into neuron-rich grafts similar to the RC17 cells. After 24 weeks, both cell lines produced DA-rich grafts that mediated full functional recovery; however, pathological changes were only observed in grafts derived from the α-synuclein triplication patient line.

CONCLUSION: This data shows proof-of-principle for survival and functional recovery with familial PD patient-derived cells in the 6-OHDA model of PD. However, signs of slowly developing pathology warrants further investigation before use of autologous grafts in patients.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Parkinson's Disease
volume
11
issue
2
pages
515 - 528
publisher
IOS Press
external identifiers
  • pmid:33361611
  • scopus:85104331818
ISSN
1877-718X
DOI
10.3233/JPD-202366
language
English
LU publication?
yes
additional info
These authors contributed equally to this work: H. Deirdre and M. Parmar
id
be0b8167-2b21-4ed3-95fc-fdbb9c2cd3b3
date added to LUP
2021-01-14 13:59:41
date last changed
2024-06-13 05:11:18
@article{be0b8167-2b21-4ed3-95fc-fdbb9c2cd3b3,
  abstract     = {{<p>BACKGROUND: Human induced pluripotent stem cells (hiPSCs) have been proposed as an alternative source for cell replacement therapy for Parkinson's disease (PD) and they provide the option of using the patient's own cells. A few studies have investigated transplantation of patient-derived dopaminergic (DA) neurons in preclinical models; however, little is known about the long-term integrity and function of grafts derived from patients with PD.</p><p>OBJECTIVE: To assess the viability and function of DA neuron grafts derived from a patient hiPSC line with an α-synuclein gene triplication (AST18), using a clinical grade human embryonic stem cell (hESC) line (RC17) as a reference control.</p><p>METHODS: Cells were differentiated into ventral mesencephalic (VM)-patterned DA progenitors using an established GMP protocol. The progenitors were then either terminally differentiated to mature DA neurons in vitro or transplanted into 6-hydroxydopamine (6-OHDA) lesioned rats and their survival, maturation, function, and propensity to develop α-synuclein related pathology, were assessed in vivo.</p><p>RESULTS: Both cell lines generated functional neurons with DA properties in vitro. AST18-derived VM progenitor cells survived transplantation and matured into neuron-rich grafts similar to the RC17 cells. After 24 weeks, both cell lines produced DA-rich grafts that mediated full functional recovery; however, pathological changes were only observed in grafts derived from the α-synuclein triplication patient line.</p><p>CONCLUSION: This data shows proof-of-principle for survival and functional recovery with familial PD patient-derived cells in the 6-OHDA model of PD. However, signs of slowly developing pathology warrants further investigation before use of autologous grafts in patients.</p>}},
  author       = {{Shrigley, Shelby and Nilsson, Fredrik and Mattsson, Bengt and Fiorenzano, Alessandro and Mudannayake, Janitha and Bruzelius, Andreas and Ottosson, Daniella Rylander and Björklund, Anders and Hoban, Deirdre B and Parmar, Malin}},
  issn         = {{1877-718X}},
  language     = {{eng}},
  month        = {{04}},
  number       = {{2}},
  pages        = {{515--528}},
  publisher    = {{IOS Press}},
  series       = {{Journal of Parkinson's Disease}},
  title        = {{Grafts Derived from an α-Synuclein Triplication Patient Mediate Functional Recovery but Develop Disease-Associated Pathology in the 6-OHDA Model of Parkinson's Disease}},
  url          = {{https://lup.lub.lu.se/search/files/100827590/SHRIGLEY_PDF_publication_in_Journal_of_Parkinson_s_Disease.pdf}},
  doi          = {{10.3233/JPD-202366}},
  volume       = {{11}},
  year         = {{2021}},
}